我国首款干细胞治疗药品上市！概念股名单一览

21世纪经济报道2025-01-03

1月3日，干细胞概念股开盘异动，截至早盘收盘，中源协和（600645.SH）涨近8%、冠昊生物（300238.SZ）涨超3%、南华生物（000504.SZ）、天士力（600535.SH）等跟涨。消息面上，1月2日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市。据民生证券介绍，干细胞在医学界被称为“万用细胞”，在特定的条件或者特定的信号诱导下能够分化成多种功能...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2500020151?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-03 14:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2500020151","market":"sh","top_or_hot":-1,"title":"我国首款干细胞治疗药品上市！概念股名单一览","media":"21世纪经济报道","content":"<div>\n<p>1月3日，干细胞概念股开盘异动，截至早盘收盘，中源协和（600645.SH）涨近8%、冠昊生物（300238.SZ）涨超3%、南华生物（000504.SZ）、天士力（600535.SH）等跟涨。消息面上，1月2日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市。据民生证券介绍，干细胞在医学界被称为“万用细胞”，在特定的条件或者特定的信号诱导下能够分化成多种功能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103141914ab9cc7e0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>我国首款干细胞治疗药品上市！概念股名单一览</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n我国首款干细胞治疗药品上市！概念股名单一览\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 14:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103141914ab9cc7e0&s=b><strong>21世纪经济报道</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月3日，干细胞概念股开盘异动，截至早盘收盘，中源协和（600645.SH）涨近8%、冠昊生物（300238.SZ）涨超3%、南华生物（000504.SZ）、天士力（600535.SH）等跟涨。消息面上，1月2日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市。据民生证券介绍，干细胞在医学界被称为“万用细胞”，在特定的条件或者特定的信号诱导下能够分化成多种功能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103141914ab9cc7e0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103141914ab9cc7e0&s=b","article_id":"2500020151","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103141914ab9cc7e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2500020151","pubTimestamp":1735884092,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"消息面上，1月2日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市。对此，南财快讯记者以投资者身份就干细胞业务分别致电中源协和、冠昊生物、南华生物，冠昊生物、南华生物工作人员均表示，公司主要涉及干细胞储存，暂无干细胞治疗药品。其中南华生物工作人员称，公司对干细胞治疗有一些研究，但未到临床阶段。文章来源：21世纪经济报道视频丨我国首款干细胞治疗药品上市！","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300238":"冠昊生物","600535":"天士力","600645":"中源协和","BK0028":"国家队","BK0239":"医药制造","BK0251":"专用设备","BK0216":"研究试验","BK0183":"MSCI概念","BK0086":"举牌","BK0282":"科技服务","BK0188":"融资融券","000504":"南华生物","BK0012":"证金概念","BK0046":"生物疫苗","BK0196":"行业龙头","BK0077":"质押式回购","BK0042":"基因检测"},"translate_title":"My country's first stem cell therapy drug is on the market! List of concept stocks","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300238":1,"600535":1,"600645":0.9,"000504":1},"content_text":"1月3日，干细胞概念股开盘异动，截至早盘收盘，中源协和（600645.SH）涨近8%、冠昊生物（300238.SZ）涨超3%、南华生物（000504.SZ）、天士力（600535.SH）等跟涨。消息面上，1月2日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市。据民生证券介绍，干细胞在医学界被称为“万用细胞”，在特定的条件或者特定的信号诱导下能够分化成多种功能细胞或组织器官；其可能应用到几乎涉及人体所有重要组织器官的修复及研究人类面临的许多医学难题，在细胞替代、组织修复、疾病治疗等方面具有巨大潜力。对此，南财快讯记者以投资者身份就干细胞业务分别致电中源协和、冠昊生物、南华生物，冠昊生物、南华生物工作人员均表示，公司主要涉及干细胞储存，暂无干细胞治疗药品。其中南华生物工作人员称，公司对干细胞治疗有一些研究，但未到临床阶段。中源协和工作人员则表示，目前进展最快的是Ⅱ期临床试验“人牙髓间充质干细胞注射液”，其他产品还有VUM02、VUM03。文章来源：21世纪经济报道原标题：视频丨我国首款干细胞治疗药品上市！概念股名单一览","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500020151","isCrawlerRequest":true}